A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
CLL/Lymphoma Follow-up Panel
Test CodeCPT Codes
88184, 88188, 88185 (x14)<br /> **This test is not available for New York patient testing**
Includes
Additional markers may be performed based on the pathologist review. These markers will be performed at an additional charge (CPT code(s): 88185 for each additional marker)
Preferred Specimen
5 mL peripheral blood collected in a sodium heparin (green-top), ACD-A (yellow-top), or EDTA (lavender-top) tube or
4 mL bone marrow collected in a sodium heparin (green-top), ACD-A (yellow-top), or EDTA (lavender-top) tube or
Tissue or body fluids: Any type is acceptable
Minimum Volume
Other Acceptable Specimens
Instructions
Peripheral blood and bone marrow: The tube must be kept at room temperature and shipped to the lab immediately.
Tissue: Any tissue type is acceptable. Tissue size is dependent upon leukocyte cellularity. (Tissue is disaggregated into single cells so that a minimum of 50,000 cells of interest are harvested.) Ship tissue in sterile plastic container with RPMI 1640 enriched with FBS (10% FBS RPMI). Absolutely no fixative should be added. Refrigerate and ship immediately.
Body fluids: Any body fluid is acceptable. Sample size is dependent upon cellularity of the sample. ( A minimum of 50,000 cells of interest in total volume of fluid). Place fluid in sterile plastic container. Absolutely no fixative should be added. Refrigerate and ship immediately.
A clinical indication and specimen source are required with each specimen. If possible, submit CBC results with differential (preferred) or an EDTA tube of peripheral blood.
Because of the critical nature of these specimens, the laboratory will attempt to process all specimens received, regardless of age of specimen. Specimens received frozen or in fixative will be rejected.
Transport Temperature
Tissue and body fluids: Refrigerated (cold packs)
Specimen Stability
Refrigerated: Not established
Frozen: Not established
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Methodology
Flow Cytometry (FC)
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Report Available
Clinical Significance
Initial markers evaluated: CD3, CD4, CD5, CD7, CD8, CD10, CD11c, CD19, CD20, CD23, CD38, HLA-Dr, sKappa, sLambda. CD45 is used for gating.